Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa

Completed

Conditions studied: HIV Infections, HIV Seronegativity

In brief

The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection. The study involves Southern African populations. The HIV-1 virus changes rapidly and many different subtypes have been found. In South Africa, limited data have suggested Subtype C HIV-1 is the most common. This study strives to verify the most common subtype and also look at genetic differences and immune responses among newly infected individuals. Results will aid in the development of vaccines specific for certain geographical areas.

Key facts

Study ID

NCT00006298

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

125

Last updated by the study team

2008-09-25

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants may be eligible for this study if they:
• Are first HIV-negative and later test HIV-positive; or are HIV-positive and have evidence of being HIV-negative within the 8 months prior to first testing HIV-positive; or are HIV-positive with one test and HIV-negative with another test.

You may not qualify if…

• Participants will not be eligible for this study if they:
• Have a mental disorder that interferes with agreeing to do the study or with participating in the study.
• Are receiving anti-HIV treatment for more than 4 weeks.
• Have tuberculosis.

Where it is running

• Missie Allen — Research Triangle Park, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.